pufa 20:4c

PUFA 20:4c refers to a specific long‑chain polyunsaturated fatty acid known as arachidonic acid (AA). Chemically defined as cis‑5,8,11,14‑eicosatetraenoic acid, it contains 20 carbon atoms and four double bonds arranged in the omega‑6 configuration. It is a major component of membrane phospholipids in many tissues, particularly the brain, muscles, liver, and immune cells. Arachidonic acid was first recognized in the early 20th century during investigations into lipid composition of biological tissues. In nutrition science it is classified as a long‑chain omega‑6 PUFA and is unique because humans obtain it both from dietary sources and through endogenous synthesis from the essential fatty acid linoleic acid via desaturase and elongase enzymes. This dual origin means that unlike alpha‑linolenic acid and linoleic acid, which must be obtained from food, arachidonic acid can be made in the body, but dietary intake still contributes significantly to tissue levels, especially in adults. Its presence in cell membranes influences membrane fluidity and interactions with enzymes and receptors that underlie many cellular signaling processes. Though traditionally discussed within the broader context of omega‑6 PUFAs, arachidonic acid has distinct biochemical roles. It is a key substrate for enzymatic pathways that produce eicosanoids—bioactive lipids including prostaglandins, thromboxanes, leukotrienes, and specialized pro‑resolving mediators that orchestrate inflammation, immunity, and homeostasis. These metabolites have potent effects on vasodilation, platelet aggregation, immune cell trafficking, and smooth muscle function. Because of its metabolic centrality, arachidonic acid is studied in contexts ranging from cardiovascular health and inflammatory diseases to cognitive and muscle physiology. While general PUFA recommendations often emphasize omega‑3 fatty acids, arachidonic acid’s contribution to human physiology remains significant, especially given its abundance in typical Western diets and its role in both pro‑ and anti‑inflammatory pathways. Imbalances between arachidonic acid and omega‑3 fatty acids can influence inflammatory status, underscoring the importance of dietary balance. Typical dietary contribution varies widely; adult intakes have been estimated in research surveys to range from approximately 50 to 300 mg/day, reflecting consumption of meats, poultry, eggs, and fish. Organ meats and egg yolk are particularly rich sources, while plant foods generally contain minimal preformed arachidonic acid but may contribute precursor linoleic acid that the body can convert. Because arachidonic acid is integral to basic cell function and signaling, its absence is rare in normal diets, but fluctuations in intake and metabolism can influence health outcomes.

Arachidonic acid’s primary biological function is serving as a precursor to a wide array of lipid mediators—collectively termed eicosanoids—which include prostaglandins, thromboxanes, leukotrienes, and lipoxins. These molecules exert potent effects in inflammatory and immune responses, platelet function, and vascular tone. Through phospholipase A2‑mediated release from membrane phospholipids, arachidonic acid is liberated and enzymatically converted by cyclooxygenases and lipoxygenases into these bioactive products that regulate vasodilation, bronchoconstriction, and leukocyte recruitment, making it central to host defense mechanisms. In immune cells, arachidonic acid metabolites modulate both the initiation and resolution phases of inflammation, demonstrating not only pro‑inflammatory roles but also contributing to signaling pathways that dampen excessive inflammatory responses. In skeletal muscle, evidence suggests arachidonic acid influences protein synthesis signaling pathways, with some trials indicating supplementation may support muscle anabolism and recovery post‑exercise, though data in adults are limited and mixed. In the central nervous system, arachidonic acid is a major constituent of phospholipids in neuronal membranes, contributing to membrane fluidity essential for synaptic function, neurotransmission, and neuroplasticity. Experimental evidence implicates arachidonic acid and its derivatives in modulating ion channel activity and second messenger systems involved in cognition and mood regulation. The systematic review literature, summarizing randomized controlled trials of increased arachidonic acid intake, found that supplementation at doses up to 1000–1500 mg/day can increase plasma levels without significantly adverse effects on blood lipids or inflammatory markers, though clear clinical benefits in adults remain insufficiently established. The metabolic balance between arachidonic acid and omega‑3 fatty acids like EPA and DHA may influence cardiovascular risk markers, with diets high in omega‑6 PUFAs generally associated with improved blood lipid profiles when replacing saturated fats. However, because arachidonic acid is a precursor to both pro‑ and anti‑inflammatory mediators, its net health impact likely depends on overall dietary context, genetic factors, and the relative abundance of competing pathways. Emerging research also explores arachidonic acid’s role in aging tissues and chronic diseases, including potential influences on bone metabolism, immune senescence, and lung function, although these areas require further clinical validation. In summary, arachidonic acid is central to key physiological processes, particularly inflammation and immunity, with implications for cardiovascular, neuromuscular, and metabolic health.

Unlike essential fatty acids such as linoleic and alpha‑linolenic acid, arachidonic acid does not have an established Recommended Dietary Allowance (RDA) from the NIH due to endogenous synthesis and lack of convincing deficiency data. Dietary surveys indicate that adult intakes in Western populations frequently range from roughly 100–250 mg/day, with estimates in some settings spanning 50–300 mg/day, reflecting variability in meat, egg, and fish consumption. In infants, arachidonic acid is present in breast milk and infant formulas to support rapid growth and brain development, highlighting its importance in early life. In older children and adults, normal diets typically provide sufficient arachidonic acid. Factors affecting needs include overall PUFA balance (omega‑6 to omega‑3 ratio), genetic polymorphisms influencing desaturase activity, and specific life stages like infancy or recovery from injury. Some experts suggest that while typical diets provide adequate arachidonic acid for membrane maintenance and basic eicosanoid production, optimal ratios with omega‑3 fatty acids may influence inflammatory outcomes. Achieving balance involves adequate intake of both classes of PUFA rather than maximizing arachidonic acid alone. No formal guidelines specify increased amounts for pregnancy or lactation beyond standard dietary patterns, because endogenous synthesis usually meets physiological needs when precursor intake is adequate.

Deficiency of arachidonic acid per se is rare in adults consuming mixed diets because the body can synthesize it from linoleic acid, provided sufficient dietary precursor. However, very low intake patterns, such as strict vegan diets with minimal linoleic acid, may result in reduced arachidonic acid status. Clinical signs associated with deficiency at the level of omega‑6 fatty acids include compromised immune responses, poor wound healing, diminished inflammatory signaling, fatigue, and potential cognitive or mood disturbances. Laboratory assessments may show lower proportions of arachidonic acid in red blood cell membranes or plasma lipid fractions. In infancy, inadequate arachidonic acid has been linked to impaired growth and neural development; for this reason, arachidonic acid is included in breast milk and many infant formulas. Because specific reference ranges are not universally agreed upon, some clinical labs express arachidonic acid as a percentage of total essential fatty acids, with suggested optimal values around 7–15% by weight, though these cut‑points vary by methodology.

Animal foods are the primary dietary sources of arachidonic acid because plant foods generally contain negligible preformed ARA. High‑source foods include organ meats such as liver and kidneys, egg yolk, and certain fish like salmon, all of which contain measurable amounts of arachidonic acid per serving. Typical organ meats provide several hundred milligrams per 100 g serving, with raw coho salmon providing approx 670 mg per 100 g, kidneys around 200–300 mg, and egg yolk around 470–480 mg per 100 g. Including a variety of these foods in meals can support arachidonic acid intake without supplementation.

Dietary arachidonic acid is absorbed with other lipids in the small intestine via micelle formation facilitated by bile acids, then incorporated into chylomicrons and transported through lymphatics before incorporation into tissue phospholipids. Its bioavailability depends on the fat content of the meal and interactions with other dietary fatty acids.

Supplementation may be considered in specific clinical contexts, such as certain infant formulas or research protocols, but routine supplementation in adults with balanced diets is usually unnecessary.

There is no formal tolerable upper intake limit established for arachidonic acid. High levels, particularly relative to omega‑3 fatty acids, may shift eicosanoid production toward pro‑inflammatory mediators.

Arachidonic acid metabolism interacts with medications that influence cyclooxygenase and lipoxygenase pathways, including NSAIDs and corticosteroids.

Common Forms: oil emulsions, combined omega‑6 supplements

Typical Doses: 100–300 mg/day from diet

When to Take: with meals containing fat

Best Form: dietary triglyceride form

⚠️ Interactions: NSAIDs, corticosteroids